Last updated: February 21, 2026
What is NDC 33342-0030?
NDC 33342-0030 corresponds to Vitrakvi (larotrectinib), developed by Bayer for treating solid tumors with neurotrophic receptor tyrosine kinase (NTRK) gene fusions. Approved by the U.S. Food and Drug Administration (FDA) in November 2018, Vitrakvi is part of a targeted therapy class for specific genetic mutations associated with multiple cancer types.
Market Overview
Indications and Off-Label Use
Vitrakvi is approved for adult and pediatric patients with NTRK gene fusion-positive solid tumors, regardless of the tumor origin. The prevalence of NTRK gene fusions varies across tumor types:
- Salivary gland carcinomas: 10-20%
- Thyroid carcinomas: 20-25%
- Pediatric gliomas: 15-25%
- Other solid tumors: <5%
It is indicated for patients with metastatic or unresectable disease, where standard therapy has limited effect.
Market Potential
The global oncology drug market is projected to reach USD 225 billion in 2026. Targeted therapies for genomically defined cancers comprise rapidly growing segments, with NTRK inhibitors expected to grow proportionally.
Key Competitors
- Entrectinib (Rozlytrek): Also by Roche, approved for NTRK-positive cancers and ROS1-positive non-small cell lung carcinoma (NSCLC). Sales in 2022: approximately USD 300 million.
- Larotrectinib (Vitrakvi): Market leader due to earliest approval; sales reached over USD 250 million in 2022.
- Other pipeline agents: Limited, but early-stage developments focus on similar genetic targets.
Adoption Rate and Market Penetration
Initial uptake was slow due to limited diagnosed cases, high cost, and competition from off-label use of other targeted therapies. Uptake increased significantly after expansion of indications and international approvals, especially in pediatric oncology.
Price and Revenue Projections
Current Pricing
- Average Wholesale Price (AWP): USD 17,000–20,000 per month per patient (source: Red Book X, 2023).
- Annual treatment cost: Approximately USD 200,000–240,000, depending on dosing and patient weight.
Cost Factors Influencing Price
- R&D investment: Approx. USD 150 million since discovery.
- Manufacturing complexity: Highly specific, antibody-like structure.
- Market exclusivity: Patent protection through at least 2030, with orphan drug designation expiring in 2031.
Projected Revenue Trends
| Year |
Estimated Annual Revenue (USD millions) |
Notes |
| 2023 |
250 |
Base case, growing recognition |
| 2024 |
350 |
Broader approvals, increased adoption |
| 2025 |
500 |
Entry into additional markets, expansion in pediatric cases |
| 2026 |
620 |
Increased competitor activity, price pressure anticipated |
Drivers of Revenue
- Expansion of indications beyond initial approvals.
- Growth in diagnosed NTRK fusion-positive tumors.
- Geographic expansion in Asia, Europe, and Latin America.
- Price adjustments in response to payer negotiations.
Risks and Challenges
- Entry of biosimilars or generics post-patent expiration.
- Regulatory hurdles and reimbursement barriers.
- Limited diagnosis rate of NTRK fusions.
- Competition from other targeted therapies.
Key Market Entry and Pricing Strategies
- Price premium maintained through FDA orphan drug and fast-track designations.
- Subscription-based models in some markets to mitigate upfront costs.
- Strategic collaborations with diagnostic companies to improve testing rates.
Conclusion
Vitrakvi (larotrectinib) maintains a strong position within the targeted cancer therapy market, with revenues projected to grow steadily through 2026. The high cost of therapy, combined with expanding indications and geographic reach, sustains substantial revenue streams. Competitive pressures and patent cliffs are potential catalysts for future price revisions.
Key Takeaways
- NDC 33342-0030 corresponds to Vitrakvi (larotrectinib), a targeted NTRK inhibitor.
- Market size is driven by diagnostic testing, incidence rates, and approval of broader indications.
- Current average annual price per patient exceeds USD 200,000.
- Revenue projections for 2023–2026 indicate growth from USD 250 million to USD 620 million.
- Key risks include generic competition post-patent expiry and diagnostic limitations.
FAQs
Q1: How many patients are eligible for Vitrakvi globally?
Estimated at several thousand annually, with the majority in the United States, Europe, and China, where diagnostic testing infrastructure is advanced.
Q2: Will prices decrease after patent expiration?
Likely, due to biosimilar entry, though timing depends on patent litigation and regulatory processes.
Q3: Has Vitrakvi shown survival benefits?
Clinical trials indicate significant response rates, but overall survival data remain limited due to the rarity of NTRK fusions.
Q4: Are there initiatives to expand testing for NTRK fusions?
Yes, several companies and clinical networks promote genetic testing to identify eligible patients.
Q5: What are the barriers to market expansion for Vitrakvi?
Limited patient diagnosis due to low prevalence of NTRK gene fusions and high testing costs.
References
- Food and Drug Administration. (2018). FDA approves larotrectinib for solid tumors with NTRK gene fusion.
- IQVIA. (2022). Global Oncology Market Report.
- Red Book X. (2023). Wholesale pharmaceutical prices.
- Bayer. (2022). Vitrakvi (larotrectinib) product information.
- EvaluatePharma. (2023). Oncology drug sales forecasts.
